Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 25, 2024 12:49pm

128 Views

Post# 36007469

RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

On the Prognostic Power of Tumor-Infiltrating Lymphocytes – A Critical Commentary

The prognostic value of tumor-infiltrating lymphocytes (TILs) in pediatric cancer is significant. Studies have shown that higher counts of CD8+ TILs in pediatric tumors are associated with better clinical outcomes, including lower tumor recurrence rates and improved disease-free survival.

https://typeset.io/papers/on-the-prognostic-power-of-tumor-infiltrating-lymphocytes-a-1kk33fqv

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario